Nasdaq

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next ...

IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily pre-treated, last-line patients with a range of solid tumors IMA402 PRAME ...
Yahoo Finance

Captain T Cell Closes Financing Round to Advance its Proprietary, Next-Generation TCR-T Pipeline Into the Clinic

Schoenefeld/Berlin, Germany, November 17, 2025 --- Captain T Cell, a biotechnology company developing next-generation TCR-T cell therapies for solid tumors, today announced the successful closing of ...
ascopubs.org

Identifying peripheral cancer-associated TCR signals for the early-detection of lung cancer.

Investigating the association of blood-to-tissue tumor mutation burden (TMB) ratio with overall survival and intratumor heterogeneity (ITH) in advanced NSCLC. This is an ASCO Meeting Abstract from the ...
Yahoo Finance

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
markets.financialcontent

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next ...

“Our off-the-shelf TCR Bispecifics have a proprietary next-generation format with half-life extension that is designed to combine optimized tolerability and potent anti-tumor activity while supporting ...